Amgen buying deCODE Genetics for $415 million

December 10, 2012 by Linda A. Johnson

Biotech pioneer Amgen Inc., in a bid for a big edge in using people's genetic information to find better ways to attack diseases, is buying human genetics research and analytics leader deCODE Genetics for $415 million.

Amgen, the world's largest by revenue, and deCODE, based in Reykjavik, Iceland, announced the all-cash deal Monday.

DeCODE, founded in 1996, has discovered for dozens of diseases, ranging from cardiovascular disease to cancer.

Probably its key asset—and the reason for the deal—is deCODE's huge database of the genetic and medical information of Iceland's population. That data can help researchers find links between genetic variations and characteristics that increase a person's risk of getting a particular disease and also affect patients' response to a drug.

" has built a world-class capability in the study of the genetics of human disease. This capability will enhance our efforts to identify and validate human disease targets," Amgen CEO Robert Bradway said in a statement.

"This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programs based on less well-validated targets," Bradway added.

That's important because the vast majority of experimental drugs, after years of expensive testing, eventually turn out not to work well or to have dangerous side effects. Drugmakers worldwide are trying to find ways to make their drug-development process more efficient to avoid spending tens of millions of dollars testing drugs that end up failing.

UBS Securities analyst Matthew Roden wrote in a note to investors that Amgen management stressed to him that being able to more efficiently identify and confirm targets for future development would help the company spot promising candidates, as well as likely failures, earlier.

"It is not surprising that Amgen is building out this R&D capability," given that some of its key experimental drugs were identified based on human genetics work, Roden wrote.

He has a "Buy" rating for Amgen and a 12-month share price target of $96, higher than its shares have ever been and significantly above its $89.95 peak over the last year. Roden noted Amgen will use off-shore cash for the deal and will not issue debt to cover it.

The board of Amgen, based in Thousand Oaks, California, has approved the deal, which does not need regulatory approval. The transaction is expected to close before year's end.

"We believe Amgen's focus and ability to incorporate our genetic research into their research and development efforts will translate our discoveries into meaningful therapies for patients," Dr. Kári Stefánsson, deCODE's founder and CEO, said in a statement.

Amgen, a biotechnology pioneer since 1980, focuses on developing powerful biologic medicines—drugs produced by living cells rather than by mixing chemicals in vats—for cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. Among its products are the anemia drugs Aranesp and Epogen, Enbrel for immune disorders and Prolia for osteoporosis.

Amgen reported sales of $15.6 billion last year and net income of $3.7 billion.

Shares of rose 73 cents to $89.05 in afternoon trading after rising as high as $89.28 per share earlier. That was just shy of its 52-week high of $89.95 set in mid-October.

Explore further: Patient privacy focus of Amgen suit

shares

Related Stories

Patient privacy focus of Amgen suit

January 9, 2008

Two former employees with the California biotech company Amgen Inc. allege the company persuaded sales people to access patient records to boost sales.

Anemia drugs under scrutiny

March 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

FDA may limit anemia drug use for kidney disease

October 14, 2010

(AP) -- The Food and Drug Administration is considering new restrictions on widely used anemia drugs that appear to double the risk of stroke in patients with kidney disease.

Amgen buys Micromet for anti-leukemia drug

January 26, 2012

Biotech giant Amgen said Thursday it was buying the German-American cancer research firm Micromet, giving it access to Micromet's promising leukemia therapy.

Amgen posts higher 2Q sales, profit to beat views

July 27, 2012

(AP) — Amgen Inc.'s second-quarter net income rose 8 percent as the world's largest biotech company benefited from higher sales for its top-selling drugs and a gain from selling its share of an experimental medicine.

Recommended for you

Solving the mystery of meningiomas reveals a surprise twist

August 23, 2016

In solving one mystery—the genetic roots of benign brain tumors called meningiomas—a team of scientists led by Yale researchers stumbled upon an even greater one: How is it possible that two of the mutations linked to ...

Two key proteins preserve vital genetic information

August 22, 2016

Cancer is often driven by various genetic mutations that are acquired through changes to a person's DNA over time. These alterations can occur at the chromosome level if the proteins are not properly organized and segregated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.